• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Xencor Inc.

    2/25/26 4:09:23 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XNCR alert in real time by email
    S-8 1 xencor-sx8x2023eip.htm S-8 Document

    As filed with the Securities and Exchange Commission on February 25, 2026
     Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ___________________________
     FORM S-8
    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
    ___________________________
    Xencor, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware20-1622502
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    465 North Halstead Street, Suite 200
    Pasadena, CA
    91107
    (Address of Principal Executive Offices)(Zip Code)
    ___________________________
    Amended and Restated
    2023 Equity Incentive Plan
    (Full title of the plan)
    ___________________________
    Bassil I. Dahiyat, Ph.D.
    President and Chief Executive Officer
    Xencor, Inc.
    465 North Halstead Street, Suite 200
    Pasadena, California 91107
    (626) 305-5900
    (Name, address and telephone number, including area code, of agent for service)
    ___________________________
    Copies to:
    Deyan P. Spiridonov
    Jeffrey T. Hartlin
    Paul Hastings LLP
    4655 Executive Drive, Suite 350
    San Diego, California 92121
    (858) 458-3044
    Celia E. Eckert
    Senior Vice President, General Counsel & Secretary
    Xencor, Inc.
    465 North Halstead Street, Suite 200
    Pasadena, California 91107
    (626) 305-5900

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
      Large accelerated filer  ☐
    Accelerated filer  ☒
      Non-accelerated filer  ☐
    Smaller reporting company  ☐
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE
    Xencor, Inc. (the “Registrant”) is filing this registration statement on Form S-8 pursuant to and in accordance with General Instruction E of Form S-8 to register 3,000,000 additional shares of its common stock, par value $0.01 per share (“Common Stock”), for issuance under the Xencor, Inc. Amended and Restated 2023 Equity Incentive Plan (the “2023 Plan”).
    These additional shares of Common Stock have become reserved for issuance pursuant to the stockholder approval received on June 12, 2025 to amend and restate the 2023 Equity Incentive Plan (the “Original 2023 Plan”) to increase the number of authorized shares of Common Stock under such plan by 3,000,000 shares.
    The Registrant first registered the offer and sale of shares of Common Stock in connection with the Original 2023 Plan on its registration statement on Form S-8 (File No. 333-272695) (the “First Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) on June 16, 2023 and on each of the following post-effective amendments filed on June 16, 2023: Post-Effective Amendment to Form S-8 (File No. 333-192635) (“POS S-8 1”), Post-Effective Amendment to  Form S-8 (File No. 333-216365) (“POS S-8 2”), Post-Effective Amendment to  Form S-8 (File No. 333-236607) (“POS S-8 3”), and Post-Effective Amendment to  Form S-8 (File No. 333-266498) (“POS S-8 4” and, together with POS S-8 1, POS S-8 2, POS S-8 3 and the First Registration Statement, the “Previous Registration Statements”).
    In accordance with General Instruction E of Form S-8, the contents of the Previous Registration Statements are hereby incorporated by reference. Only those items of Form S-8 containing new information not contained in the Previous Registration Statements are presented herein.
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3. Incorporation of Documents by Reference.
    The following documents filed with the Commission by the Registrant are hereby incorporated herein by reference:
    a)the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on February 25, 2026; and
    b)The description of the Registrant’s common stock set forth in the Registrant’s Registration Statement on Form 8-A (File No. 001-36182), filed with the SEC on November 7, 2013, including any amendments or reports filed for the purpose of updating such description, including the description of the Common Stock, contained in Exhibit 4.3 to Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025.
    All reports and other documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, on or after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such reports and other documents, except as to any portion of any such report or other document furnished under Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions. Any statement contained in a report or other document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed report or other document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
    Item 4. Description of Securities.



    Not applicable.
    Item 5. Interests of Named Experts and Counsel.
    Not applicable.
    Item 6. Indemnification of Directors and Officers.
    The Registrant is incorporated under the laws of the State of Delaware. Section 145 of the DGCL, which provides that a corporation may indemnify any persons, including officers and directors, who are, or are threatened to be made, parties to any threatened, pending or completed legal action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorney’s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such officer, director, employee or agent acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interest and, for criminal proceedings, had no reasonable cause to believe that his or her conduct was unlawful. A Delaware corporation may indemnify officers and directors in an action by or in the right of the corporation under the same conditions, except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him against the expenses that such officer or director actually and reasonably incurred.
    The Registrant’s amended and restated certificate of incorporation and second amended and restated bylaws provide for the indemnification of its directors and officers to the fullest extent permitted under the Delaware General Corporation Law.
    Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for any:
    •transaction from which the director derives an improper personal benefit;
    •act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
    •unlawful payment of dividends or redemption of shares; or
    •breach of a director’s duty of loyalty to the corporation or its stockholders.
    The Registrant’s amended and restated certificate of incorporation includes such a provision. Expenses incurred by any officer or director in defending any such action, suit or proceeding in advance of its final disposition shall be paid by the Registrant upon delivery to it of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified by the Registrant.
    Section 174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.
    As permitted by the Delaware General Corporation Law, the Registrant has entered into indemnity agreements with each of its directors and executive officers that require the Registrant to indemnify such persons against any and all costs and expenses (including attorneys’, witness or other professional fees) actually and reasonably incurred by such person in connection with any action, suit or proceeding (including derivative actions), whether actual or threatened, to which any such person may be made a party by reason of the fact that such person is



    or was a director or officer or is or was acting or serving as an officer, director, employee or agent of the Registrant or any of its affiliated enterprises, provided that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the Registrant’s best interests and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification thereunder.
    At present, there is no pending litigation or proceeding involving any of the Registrant’s directors or executive officers as to which indemnification is required or permitted, and the Registrant is not aware of any threatened litigation or proceeding that may result in a claim for indemnification.
    The Registrant has an insurance policy in place that covers its officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act or otherwise.
    Item  7. Exemption from Registration Claimed.
    Not applicable.
     Item 8. Exhibits.
    The following is a list of exhibits filed as part of this Registration Statement, which are hereby incorporated herein by reference:
    Exhibit
    Number
    Description
    4.1
    Amended and Restated Certificate of Incorporation of Xencor, Inc. (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on December 11, 2013)
    4.2
    Second Amended and Restated Bylaws of Xencor, Inc. (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Commission on February 27, 2023)
    4.3
    Form of Common Stock Certificate of Xencor, Inc. (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-191689), originally filed with the Commission on October 25, 2013)
    4.4
    Xencor, Inc. Amended and Restated 2023 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025, filed with the Commission on August 6, 2025)
    5.1*
    Opinion of Paul Hastings, LLP
    23.1
    Consent of Paul Hastings, LLP (included in Exhibit 5.1 to this Registration Statement)
    23.2*
    Consent of Independent Registered Public Accounting Firm (KPMG LLP)
    23.3*
    Consent of Independent Registered Public Accounting Firm (RSM US LLP)
    24.1
    Power of Attorney (included on the signature page of this Registration Statement)

    107*
    Filing Fee Table
    *Filed herewith




    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Pasadena, State of California, on February 25, 2026.
    XENCOR, INC.
    By:/s/ Bassil I. Dahiyat, Ph.D.
    Name:Bassil I. Dahiyat, Ph.D.
    Title:President and Chief Executive Officer
    POWER OF ATTORNEY
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Bassil I. Dahiyat, Ph.D. and Bart Jan Cornelissen, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.



    SignatureTitleDate
    /s/ Bassil I. Dahiyat, Ph.D.President, Chief Executive Officer and DirectorFebruary 25, 2026
    Bassil I. Dahiyat, Ph.D.(Principal Executive Officer)
    /s/ Bart Jan CornelissenSr. Vice President & Chief Financial Officer February 25, 2026
    Bart Jan Cornelissen(Principal Financial and Accounting Officer)
    /s/ A. Bruce Montgomery, MDDirectorFebruary 25, 2026
    A. Bruce Montgomery, MD
    /s/ Kurt A. GustafsonDirectorFebruary 25, 2026
    Kurt A. Gustafson
    /s/ Kevin C. Gorman, Ph.D.DirectorFebruary 25, 2026
    Kevin C. Gorman, Ph.D.
    /s/ Richard J. RanieriDirectorFebruary 25, 2026
    Richard J. Ranieri
    /s/ Ellen G. Feigal, M.D.DirectorFebruary 25, 2026
    Ellen G. Feigal, M.D.
    /s/ Barbara KlenckeDirectorFebruary 25, 2026
    Barbara Klencke
    /s/ Todd SimpsonDirectorFebruary 25, 2026
    Todd Simpson
    /s/ Raymond J. DeshaiesDirectorFebruary 25, 2026
    Raymond J. Deshaies


    Get the next $XNCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XNCR

    DatePrice TargetRatingAnalyst
    11/24/2025Buy
    Truist
    10/29/2025$23.00Underweight → Overweight
    Barclays
    9/17/2025$6.00Underweight
    Barclays
    9/3/2025$12.00Buy → Neutral
    BofA Securities
    4/21/2025Outperform
    William Blair
    12/12/2024$37.00Overweight
    Wells Fargo
    12/2/2024$20.00 → $30.00Neutral → Overweight
    Piper Sandler
    4/16/2024$56.00 → $38.00Buy
    BTIG Research
    More analyst ratings

    $XNCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SR. VICE PRESIDENT & CSO Desjarlais John R exercised 5,322 shares at a strike of $12.51, increasing direct ownership by 2% to 248,207 units (SEC Form 4)

    4 - Xencor Inc (0001326732) (Issuer)

    1/26/26 4:01:10 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SR. VICE PRESIDENT & CSO Desjarlais John R exercised 79,678 shares at a strike of $12.51 and sold $1,153,329 worth of shares (73,367 units at $15.72), increasing direct ownership by 3% to 242,885 units (SEC Form 4)

    4 - Xencor Inc (0001326732) (Issuer)

    12/23/25 4:02:01 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT & CEO Dahiyat Bassil I exercised 125,001 shares at a strike of $12.51 and sold $1,796,863 worth of shares (114,377 units at $15.71), increasing direct ownership by 2% to 477,259 units (SEC Form 4)

    4 - Xencor Inc (0001326732) (Issuer)

    12/23/25 4:01:38 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gorman Kevin Charles bought $1,013 worth of shares (53 units at $19.12), increasing direct ownership by 1% to 5,060 units (SEC Form 4)

    4 - Xencor Inc (0001326732) (Issuer)

    2/15/24 4:02:46 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $XNCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Truist initiated coverage on Xencor

    Truist initiated coverage of Xencor with a rating of Buy

    11/24/25 8:31:08 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor upgraded by Barclays with a new price target

    Barclays upgraded Xencor from Underweight to Overweight and set a new price target of $23.00

    10/29/25 7:51:01 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Xencor with a new price target

    Barclays resumed coverage of Xencor with a rating of Underweight and set a new price target of $6.00

    9/17/25 8:04:06 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

    -- XmAb819, novel first-in-class ENPP3 x CD3 T-cell engaging bispecific antibody, Phase 1 dose expansion in CRC, NSCLC and pRCC open to enrollment; on track to present clinical data to support a recommended Phase 3 dose in ccRCC in 2H26 -- -- Final results from healthy-volunteer study of Xmb942, Xtend™ TL1A antibody, and preclinical characterization of XmAb412, TL1A x IL23p19 XmAb® bispecific antibody, to be presented at DDW 2026 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025. "Xen

    2/25/26 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor to Participate at Upcoming Investor Conferences

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences: TD Cowen 46th Annual Health Care Conference Date: Monday, March 2, 2026 Presentation Time: 3:50 p.m. ET / 12:50 p.m. PT Leerink Partners 2026 Global Healthcare Conference Date: Tuesday, March 10, 2026 Presentation Time: 10:00 a.m. ET / 7:00 a.m. PT Barclays 28th Annual Global Healthcare Conference Date: Wednesday, March 11, 2026 Presentation Time: 11:30 a.m. ET / 8:30 a.m. PT Live webcasts of the presentations will be av

    2/23/26 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026 pipeline advancement milestones for its clinical-stage portfolio of novel XmAb® drug candidates. "Xencor designs proteins that enable potential first-in-class and best-in-class medicines for patients, and we are building on momentum from 2025, when we presented encouraging clinical data from our portfolio of T-cell engagers and TL1A antibodies," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "We are excited to be evaluating a pipeline of five wholly owned clin

    1/8/26 8:01:00 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    SEC Filings

    View All

    SEC Form S-8 filed by Xencor Inc.

    S-8 - Xencor Inc (0001326732) (Filer)

    2/25/26 4:09:23 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Xencor Inc.

    S-3ASR - Xencor Inc (0001326732) (Filer)

    2/25/26 4:06:18 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Xencor Inc.

    10-K - Xencor Inc (0001326732) (Filer)

    2/25/26 4:02:27 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Financials

    Live finance-specific insights

    View All

    Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

    -- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort -- -- Management hosting webcast and conference call today at 1:30 p.m. ET / 10:30 a.m. PT -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with a

    10/24/25 12:30:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24 at 1:30 p.m. ET (10:30 a.m. PT) to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma. The live webcast of the conference call may be accessed through this link and through "Events & Presentations" in the Investors section of the Company's website, located at investors.xencor.com. A recording will be available for at l

    10/21/25 8:01:00 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

    10/17/25 9:50:00 AM ET
    $EDAP
    $EVAX
    $GTBP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    $XNCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Xencor Inc.

    SC 13G/A - Xencor Inc (0001326732) (Subject)

    11/14/24 6:16:13 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xencor Inc.

    SC 13G/A - Xencor Inc (0001326732) (Subject)

    11/14/24 1:22:36 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xencor Inc.

    SC 13G/A - Xencor Inc (0001326732) (Subject)

    11/12/24 4:01:23 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Leadership Updates

    Live Leadership Updates

    View All

    Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies is a pioneering biochemist and cell biologist with more than 25 years of experience in biotechnology and drug development. He recently served as senior vice president of global research at Amgen Inc., where he oversaw all research activities, including the nomination of over 50 clinical candidates, expansion of Amgen's capabilities for discovering and optimizing multispecific drug candidates, and application of generative protein desig

    7/31/25 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Appoints Todd Simpson to Board of Directors

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023. "Mr. Simpson is an accomplished finance and operations executive with broad experience in corporate strategy, and he played a key role in transforming a small development-stage biotech company into one of the most successful growth c

    3/13/25 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Appoints Bart Cornelissen as Chief Financial Officer

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at Seagen Inc., where he was instrumental in the company's transformation into a global, multi-product organization that generated over $2 billion in annual revenue. "Bart's exceptional track record in financial planning and analysis

    4/9/24 8:01:00 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care